Eli Lilly And Company

This study tests whether adding an experimental drug called brenipatide to standard treatment (buprenorphine) helps people with opioid use disorder stay off opioids longer. About 465 participants will receive either brenipatide or a placebo injection over many weeks. The goal is …

This early-stage study tests a new drug called brenipatide in healthy adults who are overweight or have obesity. The goal is to see how well different doses help with weight loss and whether they are safe. Participants will receive injections under the skin and be followed for ab…

This study tests a new medicine called LY3938577 against a standard insulin (degludec) in 100 adults with type 2 diabetes who already use basal insulin. The goal is to see if the new drug helps keep blood sugar in a healthy range more safely and effectively over about 26 weeks. P…

This study tests whether adding tirzepatide (a weight-loss drug) to mirikizumab (an anti-inflammatory drug) helps adults with moderate-to-severe Crohn's disease who are also overweight or obese. About 290 participants will receive either mirikizumab alone or mirikizumab plus tirz…

This study tests a new once-weekly injection called eloralintide to help people with obesity or overweight and type 2 diabetes lose weight. About 1035 adults will receive either the drug or a placebo for 75 weeks. The main goal is to see how much weight they lose and whether it a…

This study tests a new weekly injection, LY3457263, in adults with type 2 diabetes whose blood sugar is still too high despite taking stable doses of semaglutide or tirzepatide. About 240 participants will receive either the new drug or a placebo for roughly 9 months. The main go…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments can better control advanced non-small cell lung cancer with a specific KRAS G12C gene change. About 1,264 people with untreated, advanced disease will receive either the new drug combo or stand…

This study tests a once-weekly injection called eloralintide to help adults with obesity or overweight (without type 2 diabetes) lose weight. About 1,980 participants will receive either the drug or a placebo for 75 weeks, with some continuing for up to 2 more years. The main goa…

This study tests whether adding the experimental drug LY4064809 to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+, HER2- breast cancer that has a PIK3CA mutation. About 920 adults who have not yet received treatment for their advanced cancer will …

This study tests a new drug, LY3537982, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile du…

This early-stage study tests a new drug called LY4256984 in 32 people with sporadic ALS. The drug is given as an injection into the spine to see if it is safe and what side effects it may cause. Researchers will also measure how much drug gets into the blood and how the body proc…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard treatments. The drug is designed to seek out and attack cancer cells carrying a specific marker (PTK7). The main goals are…

This study tests a new oral drug, pirtobrutinib, in adults with immune thrombocytopenia (ITP) who have not responded well to other treatments. The first part finds a safe dose, and the second part compares the drug to a placebo to see if it can raise platelet counts. About 58 peo…

This early-stage study tests a new medicine called LY4298445 in healthy volunteers and people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. About 63 participants will receive either the drug or a placebo, and the …

This study tests a new treatment called LY4257496 for people with advanced breast, colorectal, prostate, or endometrial cancer that has spread. The treatment delivers radiation directly to cancer cells that have a specific protein (GRPR). The goal is to see if it is safe and shri…

This study tests whether adding a new medicine called vepugratinib to two standard cancer drugs (enfortumab vedotin and pembrolizumab) works better than a placebo plus the same two drugs for people with advanced or spreading bladder cancer that has a specific FGFR3 gene change. A…

This study tests two higher doses of the diabetes drug dulaglutide in 55 teenagers aged 10 to 17 who have type 2 diabetes. Participants must already be on metformin or basal insulin. The goal is to see if the higher doses are safe and help control blood sugar and weight over abou…

This study tests whether adding a new drug (LY4268989) to an existing treatment (mirikizumab) works better than mirikizumab alone for adults with moderate-to-severe ulcerative colitis. About 252 participants will receive either the combination or mirikizumab alone for up to 2 yea…

This study tests a drug called mirikizumab in children aged 2 to 17 with moderate-to-severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can help control the disease and improve symptoms. About 60 children will take part, and they will receive the d…

This study looks at whether adding tirzepatide (a drug used for diabetes and weight loss) to the standard psoriatic arthritis treatment ixekizumab helps people with active psoriatic arthritis who are also overweight or obese. About 200 adults will take both drugs for up to 12 mon…

This study tests whether a once-daily tablet called orforglipron can reduce episodes of stress urinary incontinence (leaking urine during activity) in women who have obesity or overweight. About 1000 adult women will receive either the drug or a placebo for up to 58 weeks. The ma…

This study tests if the drug lebrikizumab can reduce itch and skin symptoms in adults and teenagers with moderate eczema who have severe itching. About 200 participants will receive the drug for 24 weeks and be followed for up to 38 weeks. The main goal is to see if the treatment…

This early-stage study tests a new drug called LY4064912 in healthy volunteers and people with overweight or obesity. The main goal is to see if the drug is safe and what side effects it may cause. Researchers will also measure how the body processes the drug and its effect on bo…

This phase 3 study tests a once-weekly medicine called eloralintide in 900 adults who have osteoarthritis of the knee and are overweight or have obesity. The goal is to see if the drug reduces knee pain and body weight better than a placebo. Participants will be in the study for …

This study tests a once-daily medication called orforglipron in people with peripheral artery disease (PAD), a condition that causes leg pain while walking due to narrowed arteries. The goal is to see if the drug can increase how far participants can walk without pain and improve…

This study looks at how the body processes a new drug called eloralintide in people with severe kidney disease or kidney failure compared to healthy people. About 28 adults will receive a single injection under the skin. The goal is to measure drug levels in the blood and how lon…